Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron-chelation therapy: an update.

Massimo Franchini1, Dino Veneri

  • 1Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy. mfranchini@mail.univr.it

The Hematology Journal : the Official Journal of the European Haematology Association
|August 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual case of sodium citrate-dependent artifactual platelet count.

Interventional medicine & applied science·2022
Same author

Pathogenesis of immune thrombocytopenia in common variable immunodeficiency.

Autoimmunity reviews·2020
Same author

Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

Tumori·2019
Same author

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

Haematologica·2019
Same author

Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs.

Frontiers in pharmacology·2018
Same author

Primary sphenoid lymphoma: Focus on imaging.

Tumori·2018
Same journal

Acute myocardial infarction in sickle cell disease: a possible complication of hydroxyurea treatment.

The hematology journal : the official journal of the European Haematology Association·2005
Same journal

Plasma nitric oxide levels used as an indicator of doxorubicin-induced cardiotoxicity in rats.

The hematology journal : the official journal of the European Haematology Association·2005
Same journal

The effect of iron deficiency anemia on the function of the immune system.

The hematology journal : the official journal of the European Haematology Association·2005
Same journal

Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.

The hematology journal : the official journal of the European Haematology Association·2005
Same journal

Malignant diseases of hematopoietic and lymphoid tissues in Chernobyl clean-up workers.

The hematology journal : the official journal of the European Haematology Association·2005
Same journal

Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.

The hematology journal : the official journal of the European Haematology Association·2005
See all related articles

Iron overload in chronically transfused patients can be managed with iron chelating agents. New treatments, including oral iron chelators and alternative desferrioxamine mesylate administration, improve patient compliance and outcomes.

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic blood transfusions lead to iron overload, causing organ damage and mortality.
  • Desferrioxamine mesylate (DFO) improved life expectancy but requires demanding continuous infusion.
  • Need for improved patient compliance drives development of alternative iron chelation therapies.

Purpose of the Study:

  • To review significant advancements in iron-chelating therapy.
  • To analyze novel administration methods for desferrioxamine mesylate.
  • To evaluate new orally active iron chelators and combination therapies.

Main Methods:

  • Review of recent literature on iron-chelating agents.
  • Analysis of a new twice-daily subcutaneous bolus injection method for DFO.

Related Experiment Videos

  • Evaluation of the oral iron chelator ICL670A.
  • Meta-analysis of trials on oral deferiprone and combined DFO/deferiprone therapy.

    • Main Results:

    • Alternative DFO administration (bolus injections) enhances patient compliance.
    • Orally active iron chelators like ICL670A offer a more convenient treatment option.
    • Meta-analysis provides insights into the efficacy of deferiprone and combination therapy.

    Conclusions:

    • Advances in iron chelation therapy offer improved compliance and potentially better outcomes for patients with iron overload.
    • Novel administration routes and oral agents represent significant progress in managing transfusion-dependent iron overload.
    • Combined therapies may offer synergistic benefits in iron chelation management.